What is B. Riley’s Estimate for DNLI FY2029 Earnings?

Denali Therapeutics Inc. (NASDAQ:DNLI) – Research analysts at B. Riley issued their FY2029 EPS estimates for shares of Denali Therapeutics in a research report issued on Wednesday, March 5th. B. Riley analyst M. Mamtani expects that the company will post earnings per share of $0.87 for the year. B. Riley has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share.

Several other research analysts have also recently issued reports on the company. The Goldman Sachs Group cut their price objective on Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. JPMorgan Chase & Co. reduced their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a research note on Tuesday, January 7th. HC Wainwright boosted their price objective on shares of Denali Therapeutics from $80.00 to $87.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Robert W. Baird began coverage on Denali Therapeutics in a research note on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 price objective for the company. Finally, Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a research report on Monday, December 16th. Two research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Denali Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $37.57.

Denali Therapeutics Price Performance

DNLI opened at $16.30 on Thursday. Denali Therapeutics has a 12 month low of $14.01 and a 12 month high of $33.33. The stock has a market capitalization of $2.35 billion, a P/E ratio of -5.91 and a beta of 1.43. The business has a 50 day simple moving average of $21.07 and a 200-day simple moving average of $24.46.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.08.

Hedge Funds Weigh In On Denali Therapeutics

A number of hedge funds have recently added to or reduced their stakes in DNLI. Sterling Capital Management LLC raised its holdings in shares of Denali Therapeutics by 589.9% during the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company’s stock worth $36,000 after purchasing an additional 1,516 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Denali Therapeutics during the 4th quarter valued at about $62,000. Point72 Hong Kong Ltd acquired a new stake in Denali Therapeutics during the fourth quarter worth about $65,000. Quest Partners LLC bought a new position in Denali Therapeutics in the third quarter worth about $73,000. Finally, PNC Financial Services Group Inc. boosted its stake in Denali Therapeutics by 30.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock valued at $77,000 after acquiring an additional 885 shares during the period. Institutional investors and hedge funds own 92.92% of the company’s stock.

Insider Buying and Selling at Denali Therapeutics

In related news, Director Vicki L. Sato sold 3,080 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the sale, the director now directly owns 107,976 shares of the company’s stock, valued at $2,257,778.16. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Carole Ho sold 12,255 shares of Denali Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $20.22, for a total value of $247,796.10. Following the completion of the transaction, the insider now owns 178,580 shares of the company’s stock, valued at approximately $3,610,887.60. The trade was a 6.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 47,940 shares of company stock valued at $973,442 in the last ninety days. Insiders own 7.90% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.